ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma
Feng Ji(Fudan University), Guo‐Dong Lu(Guangxi University)
Cited by 161
Related Papers
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
|Acta Pharmacologica Sinica|2020|300
Fatty acid activation in carcinogenesis and cancer development: Essential roles of long‑chain acyl‑CoA synthetases (Review)
|Oncology Letters|2018|154
Activating AMP-activated protein kinase by an α1 selective activator compound 13 attenuates dexamethasone-induced osteoblast cell death
|Biochemical and Biophysical Research Communications|2016|59
PP2A catalytic subunit silence by microRNA-429 activates AMPK and protects osteoblastic cells from dexamethasone
|Biochemical and Biophysical Research Communications|2017|45